AKBA NASDAQ
Akebia Therapeutics, Inc.
1W: -3.5%
1M: -11.8%
3M: -33.5%
YTD: -44.2%
1Y: -67.7%
3Y: -24.8%
5Y: -69.8%
$0.86
-0.01 (-0.69%)
Weekly Expected Move ±7.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
21 relationships18
As Filer
counterparties named
3
As Counterparty
mentioned by others
3
Rel. Types
2021-06-04
Earliest Filing
2025-12-01
Latest Filing
partner: 11
supplier: 5
acquirer: 2
Counterparties (Filed by AKBA)
18 relationshipsCompanies named in AKBA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Q32 Bio Inc. | QTTB | acquirer | Sold and assigned assets related to ADX-097 to Akebia Therapeutics, Inc. | 2025-12-01 | View |
| Q32 Bio Operations Inc. | QTTB | acquirer | Sold and assigned assets related to ADX-097 to Akebia Therapeutics, Inc. | 2025-12-01 | View |
| Cyclerion Therapeutics, Inc. | CYCN | partner | Licensee under an existing License Agreement with Akebia Therapeutics, Inc. | 2025-12-01 | View |
| MEDICE ARZNEIMITTEL PUTTER GMBH & CO. KG | — | partner | Exclusive license agreement for Vafseo development and commercialization in Europe | 2025-11-17 | View |
| STA Pharmaceutical Hong Kong Limited | — | supplier | Manufactures vadadustat drug product for Akebia Therapeutics, Inc. | 2024-10-16 | View |
| CSL Limited | CSL | partner | Parent company of CSL Vifor, party to termination and settlement agreement | 2024-07-11 | View |
| BlackRock Inc. | BLK | partner | Fund manager for Kreos Capital VII (UK) Limited | 2024-07-11 | View |
| STA Pharmaceutical Hong Kong Limited | — | supplier | Manufactures vadadustat drug substance for Akebia Therapeutics, Inc. | 2024-04-16 | View |
| MEDICE Arzneimittel Pütter GmbH & Co. KG | — | partner | Exclusive license agreement for vadadustat development and commercialization in specific territories | 2023-05-25 | View |
| Keryx Biopharmaceuticals, Inc. | — | supplier | Wholly-owned subsidiary of Akebia Therapeutics, Inc. that entered into an amendment to a manufacturing supply agreement. | 2023-03-02 | View |
| Siegfried Evionnaz SA | — | supplier | Counterparty to the amended Master Manufacturing Services and Supply Agreement for drug substance. | 2023-03-02 | View |
| Keryx Biopharmaceuticals, Inc. | — | partner | Wholly-owned subsidiary of Akebia Therapeutics, Inc. that entered into a license agreement with Averoa and a termination | 2022-12-28 | View |
| Averoa SAS | — | partner | Entered into an exclusive license agreement with Akebia Therapeutics, Inc. to develop and commercialize ferric citrate i | 2022-12-28 | View |
| BioVectra Inc. | — | supplier | Supplier of ferric citrate drug substance to Akebia Therapeutics, Inc. whose agreements were terminated via a settlement | 2022-12-28 | View |
| Vifor (International) Ltd. | — | partner | Counterparty to the Second Amended and Restated Vifor License Agreement | 2022-07-18 | View |
| Otsuka Pharmaceutical Co. Ltd. | — | partner | Termination and settlement of collaboration and license agreements regarding vadadustat | 2022-06-30 | View |
| Jefferies LLC | JEF | partner | Acted as sales agent for the Open Market Sale Agreement. | 2022-04-07 | View |
| Cantor Fitzgerald & Co. | — | partner | Previous sales agent whose agreement was terminated. | 2022-04-07 | View |
Mentioned As Counterparty
3 mentionsOther companies that named AKBA in their SEC 8-K filings.
| Filed By | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|
| QTTB Q32 Bio Inc. | target | Acquired substantially all assets related to ADX-097 from Q32 Bio Inc. | 2025-12-01 | View |
| CYCN Cyclerion Therapeutics, Inc. | partner | Amendment to License Agreement involving royalty rate adjustments and patent control transfer | 2024-12-17 | View |
| CYCN Cyclerion Therapeutics, Inc. | partner | Entered into a License Agreement for exclusive worldwide rights to develop and commercialize praliciguat products. | 2021-06-04 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-06-30 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-05-07 | Earnings Release; Exhibits | View | |
| 2026-04-01 | Officer/Director Change; Exhibits | View | |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-30 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Departure/Electio | Agreement | View |
| 2026-01-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View | |
| 2025-12-01 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2025-11-17 | Entry into Material Definitive Agreement | Agreement | View |
| 2025-11-10 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-28 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-06-13 | Departure/Election of Directors; Appointment of Officers; Submission of Matters to a Vote of Securit | View | |
| 2025-05-08 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-03-20 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2025-03-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-02-07 | Entry into Material Definitive Agreement; Creation of Direct Financial Obligation; Unregistered Sale | Agreement | View |
| 2025-01-13 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2024-11-07 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2024-10-22 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR